Updated Incidence, Treatment and Survival of a Nationwide Cohort of Patients with Peritoneal Metastases of Unknown Origin.

Autor: Rijken A; Department of Surgery, Catharina Cancer Institute, Eindhoven, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands., Loef C; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands., van de Wouw YAJ; Department of Medical Oncology, VieCuri Hospital, Venlo/Venray, the Netherlands., van Erning FN; Department of Surgery, Catharina Cancer Institute, Eindhoven, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands., de Hingh IHJT; Department of Surgery, Catharina Cancer Institute, Eindhoven, Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.; GROW- School for Oncology and Development Biology, Maastricht University, Maastricht, the Netherlands.

Publikováno v: Indian journal of surgical oncology [Indian J Surg Oncol] 2023 Jun; Vol. 14 (Suppl 1), pp. 67-73. Date of Electronic Publication: 2022 Jun 21.

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry.

Autor: Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Kuppen MCP; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands., van den Eertwegh FAJM; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van Oort IM; Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands., Coenen JLLM; Department of Oncology, Isala, Zwolle, the Netherlands., van Moorselaar JRJA; Department of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands., Aben KKH; Department of Health Evidence, and Radboud University Medical Center, Nijmegen, the Netherlands.; Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands., Bergman AM; Division of Medical Oncology, the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Huinink DTB; Department of Internal Medicine, Diakonessenhuis, Utrecht, the Netherlands., van den Bosch J; Department of Internal Medicine, Albert Schweitzer Ziekenhuis, Dordrecht, the Netherlands., Hendriks MP; Department of Internal Medicine, Northwest Clinics, Alkmaar, the Netherlands., Lampe MI; Department of Urology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Lavalaye J; Department of Nuclear Medicine, St Antonius Hospital, Nieuwegein, the Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Smilde TJ; Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Somford RDM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands., Tick L; Department of Internal Medicine, Maxima Medical Center, Eindhoven, the Netherlands., Weijl NI; Department of Internal Medicine, MCH-Bronovo Hospital, 's-Gravenhage, the Netherlands., van de Wouw YAJ; Department of Internal Medicine, VieCuri Medical Center, Venlo, the Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Groot CAU; Institute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.

Publikováno v: Journal of palliative medicine [J Palliat Med] 2021 Dec; Vol. 24 (12), pp. 1789-1797. Date of Electronic Publication: 2021 Aug 19.

Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group.

Autor: Kwakman JJM; Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: j.j.kwakman@amc.uva.nl., van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands., Simkens LHJ; Department of Medical Oncology, Maxima Medical Center, Eindhoven, the Netherlands., van Rooijen JM; Department of Medical Oncology, Martini Hospital, Groningen, the Netherlands., van de Wouw YAJ; Department of Medical Oncology, VieCuri Medical Center, Venlo, the Netherlands., Tije AJT; Department of Medical Oncology, Amphia Hospital, Breda, the Netherlands., Creemers GM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Hendriks MP; Department of Medical Oncology, Northwest Clinics, Alkmaar, the Netherlands., Los M; Department of Medical Oncology, Sint Antonius Hospital, Nieuwegein, the Netherlands., van Alphen RJ; Department of Medical Oncology, TweeSteden Hospital, Tilburg, the Netherlands., Polée MB; Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Muller EW; Department of Medical Oncology, Slingeland Hospital, Doetinchem, the Netherlands., van der Velden AMT; Department of Medical Oncology, Tergooi Hospital, Hilversum, the Netherlands., van Voorthuizen T; Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands., Koopman M; Department of Medical Oncology, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands., Mol L; Clinical Trial Department, Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, the Netherlands., Punt CJA; Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Publikováno v: Clinical colorectal cancer [Clin Colorectal Cancer] 2019 Jun; Vol. 18 (2), pp. e229-e230. Date of Electronic Publication: 2019 Jan 29.